Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer

Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.